Literature DB >> 24952023

The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review.

Divi Cornec1,2,3, Alain Saraux1,2,3, Sandrine Jousse-Joulin1,2,3, Jacques-Olivier Pers2,3,4, Sylvie Boisramé-Gastrin4, Yves Renaudineau2,3,4,5, Yves Gauvin6, Anne-Marie Roguedas-Contios7, Steeve Genestet8, Myriam Chastaing9, Béatrice Cochener10, Valérie Devauchelle-Pensec11,12,13,14.   

Abstract

Primary Sjögren's syndrome (pSS) is a frequent autoimmune systemic disease, clinically characterized by eyes and mouth dryness in all patients, salivary gland swelling or extraglandular systemic manifestations in half of the patients, and development of lymphoma in 5 to 10 % of the patients. However, patients presenting with sicca symptoms or salivary gland swelling may have a variety of conditions that may require very different investigations, treatments, or follow-up. Eye and/or mouth dryness is a frequent complaint in clinical setting, and its frequency increases with age. When evaluating a patient with suspected pSS, the first step is to rule out its differential diagnoses, before looking for positive arguments for the disease. Knowledge of normal and abnormal lachrymal and salivary gland physiology allows the clinician to prescribe the most adapted procedures for evaluating their function and structure. New tests have been developed in recent years for evaluating these patients, notably new ocular surface staining scores or salivary gland ultrasonography. We describe the different diagnoses performed in our monocentric cohort of 240 patients with suspected pSS. The most frequent diagnoses are pSS, other systemic autoimmune diseases, idiopathic sicca syndrome and drug-induced sicca syndrome. However, other diseases are important to rule out due to their specific management, such as sarcoidosis, granulomatosis with polyangeitis, IgG4-related disease, chronic hepatitis C virus or human immunodeficiency virus infections, graft-versus-host disease, and head and neck radiation therapy. At the light of these data, we propose a core of minimal investigations to be performed when evaluating a patient with suspected pSS.

Entities:  

Keywords:  Diagnosis; Salivary gland swelling; Sjögren’s syndrome; Xerophtalmia; Xerostomia

Mesh:

Year:  2015        PMID: 24952023     DOI: 10.1007/s12016-014-8431-1

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  64 in total

1.  Salivary gland echography in primary and secondary Sjögren's syndrome.

Authors:  S De Vita; G Lorenzon; G Rossi; M Sabella; V Fossaluzza
Journal:  Clin Exp Rheumatol       Date:  1992 Jul-Aug       Impact factor: 4.473

Review 2.  Epidemiology of Sjögren's syndrome: where are we now?

Authors:  A Binard; V Devauchelle-Pensec; B Fautrel; S Jousse; P Youinou; A Saraux
Journal:  Clin Exp Rheumatol       Date:  2007 Jan-Feb       Impact factor: 4.473

3.  A prospective study of sicca symptoms in patients with rheumatoid arthritis.

Authors:  Johan G Brun; Tor Magne Madland; Roland Jonsson
Journal:  Arthritis Rheum       Date:  2003-04-15

4.  Images in clinical medicine. Heerfordt's syndrome, or uveoparotid fever.

Authors:  Anisha Dua; Augustine Manadan
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

5.  Xerostomia and associated factors in a community-dwelling adult population.

Authors:  R J Billings; H M Proskin; M E Moss
Journal:  Community Dent Oral Epidemiol       Date:  1996-10       Impact factor: 3.383

Review 6.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

Review 7.  Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: a systematic review.

Authors:  Dewi Guellec; Divi Cornec; Sandrine Jousse-Joulin; Thierry Marhadour; Pascale Marcorelles; Jacques-Olivier Pers; Alain Saraux; Valérie Devauchelle-Pensec
Journal:  Autoimmun Rev       Date:  2012-08-07       Impact factor: 9.754

8.  Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort.

Authors:  Astrid Rasmussen; John A Ice; He Li; Kiely Grundahl; Jennifer A Kelly; Lida Radfar; Donald U Stone; Kimberly S Hefner; Juan-Manuel Anaya; Michael Rohrer; Rajaram Gopalakrishnan; Glen D Houston; David M Lewis; James Chodosh; John B Harley; Pamela Hughes; Jacen S Maier-Moore; Courtney G Montgomery; Nelson L Rhodus; A Darise Farris; Barbara M Segal; Roland Jonsson; Christopher J Lessard; R Hal Scofield; Kathy L Moser Sivils
Journal:  Ann Rheum Dis       Date:  2013-08-22       Impact factor: 19.103

Review 9.  Dry eye: diagnosis and current treatment strategies.

Authors:  Paul D O'Brien; Louis M T Collum
Journal:  Curr Allergy Asthma Rep       Date:  2004-07       Impact factor: 4.919

10.  Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepancies.

Authors:  Divi Cornec; Alain Saraux; Béatrice Cochener; Jacques-Olivier Pers; Sandrine Jousse-Joulin; Yves Renaudineau; Thierry Marhadour; Valérie Devauchelle-Pensec
Journal:  Arthritis Res Ther       Date:  2014-03-19       Impact factor: 5.156

View more
  17 in total

Review 1.  The Diagnosis and Treatment of Sjögren's Syndrome.

Authors:  Ana-Luisa Stefanski; Christian Tomiak; Uwe Pleyer; Thomas Dietrich; Gerd Rüdiger Burmester; Thomas Dörner
Journal:  Dtsch Arztebl Int       Date:  2017-05-26       Impact factor: 5.594

Review 2.  Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults.

Authors:  Alan N Baer; Brian Walitt
Journal:  Rheum Dis Clin North Am       Date:  2018-08       Impact factor: 2.670

Review 3.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

4.  [Swelling of the submandibular and parotid glands : A description of possible differential diagnoses].

Authors:  B Hofauer; A Chaker; T Strenger; M Bas; N Mansour; A Knopf
Journal:  HNO       Date:  2016-05       Impact factor: 1.284

Review 5.  Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Authors:  Elena Generali; Antonio Costanzo; Carlo Mainetti; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

6.  Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort.

Authors:  Gabriel Maciel; Cynthia S Crowson; Eric L Matteson; Divi Cornec
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

7.  A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.

Authors:  Hao Guo; Changrim Lee; Mihir Shah; Srikanth R Janga; Maria C Edman; Wannita Klinngam; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2018-10-23       Impact factor: 9.776

Review 8.  Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.

Authors:  Laurent Simonin; Elisabeth Pasquier; Christophe Leroyer; Divi Cornec; Julie Lemerle; Boutahar Bendaoud; Sophie Hillion; Jacques-Olivier Pers; Francis Couturaud; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 9.  Significance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.

Authors:  Takanori Fujimura; Takashi Fujimoto; Asako Itaya-Hironaka; Tomoko Miyaoka; Kiyomi Yoshimoto; Sumiyo Sakuramoto-Tsuchida; Akiyo Yamauchi; Maiko Takeda; Hiroki Tsujinaka; Yasuhito Tanaka; Shin Takasawa
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 10.  Ocular Involvement in Systemic Autoimmune Diseases.

Authors:  Elena Generali; Luca Cantarini; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.